Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

iTeos Therapeutics, Inc. - Common Stock (NQ:ITOS)

5.460 -0.240 (-4.21%)
Streaming Delayed Price Updated: 9:41 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,475
Open 5.490
Bid (Size) 5.440 (2)
Ask (Size) 5.490 (3)
Prev. Close 5.700
Today's Range 5.370 - 5.530
52wk Range 5.470 - 18.75
Shares Outstanding 35,763,742
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
From iTeos Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-30.9%
-30.9%
1 Month
-20.3%
-20.3%
3 Month
-30.9%
-30.9%
6 Month
-43.6%
-43.6%
1 Year
-58.4%
-58.4%

More News

Read More
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
From iTeos Therapeutics Inc.
Via GlobeNewswire
The One-Minute Market Report - Sunday, Sept. 22
Via Talk Markets
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Via Investor's Business Daily
Topics Death
Exposures Death
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
From iTeos Therapeutics Inc.
Via GlobeNewswire
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
From iTeos Therapeutics Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024
Via InvestorPlace

Frequently Asked Questions

Is iTeos Therapeutics, Inc. - Common Stock publicly traded?
Yes, iTeos Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does iTeos Therapeutics, Inc. - Common Stock trade on?
iTeos Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for iTeos Therapeutics, Inc. - Common Stock?
The ticker symbol for iTeos Therapeutics, Inc. - Common Stock is ITOS on the Nasdaq Stock Market
What is the current price of iTeos Therapeutics, Inc. - Common Stock?
The current price of iTeos Therapeutics, Inc. - Common Stock is 5.460
When was iTeos Therapeutics, Inc. - Common Stock last traded?
The last trade of iTeos Therapeutics, Inc. - Common Stock was at 04/04/25 09:41 AM ET
What is the market capitalization of iTeos Therapeutics, Inc. - Common Stock?
The market capitalization of iTeos Therapeutics, Inc. - Common Stock is 195.27M
How many shares of iTeos Therapeutics, Inc. - Common Stock are outstanding?
iTeos Therapeutics, Inc. - Common Stock has 195M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.